Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant human endostatin adenovirus
- Development stage
- Phase 3
- Lead developer
- Sun Yat-sen University
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
Recombinant human endostatin adenovirus is a gene therapy drug that uses a replication-defective type 5 adenoviral vector to deliver the gene encoding human endostatin directly into tumor tissue. Endostatin is a potent endogenous inhibitor of angiogenesis, derived from collagen XVIII. After intratumoral injection, the virus infects tumor cells and expresses high levels of human endostatin protein locally within the tumor microenvironment. This leads to inhibition of proliferation and migration of vascular endothelial cells, induction of apoptosis in these cells, suppression of new blood vessel formation (angiogenesis), and ultimately blocks oxygen and nutrient supply to tumors—effectively "starving" them. The therapy also induces anti-tumor immune responses by turning immunologically "cold" tumors into "hot" ones. It has been studied primarily for advanced head and neck squamous cell carcinoma and nasopharyngeal carcinoma in combination with chemotherapy[1][4][5].
- Brand names
- E10AE-10AE 10A
- Other names
- adenovirus encoding recombinant human endostatinrecombinant human endostatin adenovirus injection
02
Targets
ITGA5:ITGB1 (Integrin α5β1)αVβ3 (Integrin αVβ3)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on Recombinant human endostatin adenovirus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recombinant human endostatin adenovirus.